Cost-effectiveness analysis of tafluprost versus latanoprost in the treatment of primary open-angle glaucoma

胡春阳,韩晟,陈路佳,张慕禹,洪冬喆,杨照,史录文
2013-01-01
Abstract:Objective: To conduct an economic review of tafluprost vs. latanoprost in the treatment of primary open-angle glaucoma (POAG) in order to obtain a cost-effective reference price range for tafluprost and also to contribute to clinical rational drug using. Methods: Population characteristics, effectiveness and safety data were extracted from a multi-center, single-blind, parallel controlled, 4-week phase III domestic clinical trial in 196 POAG patients. Treatment costs consisted of direct medical costs, direct nonmedical cost and indirect costs, which were calculated from a social perspective. A decision tree model was constructed to conduct a cost-effectiveness analysis, followed by a sensitivity analysis. Results: Effectiveness indicator was defined as percentage of patients with IOP declining rate ≥25% at 17:00 on the 28th day of monotherapy process. Effectiveness for tafluprost group and latanoprost group was 82.3% and 80.0%, and their C/E ratios were 1 849.2+0.799x and 2066.8+0.00378x, respectively. ICER is 28.752x-5798.4. A cost-effective price range for tafluprost was calculated as x<¥313 per bottle. Conclusion: The cost-effective price range for tafluprost is x<¥313 per bottle compared with latanoprost in the treatment of primary open-angle glaucoma.
What problem does this paper attempt to address?